¿¬¼ö°­ÁÂ
¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷) : 2024-04-25

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷) : 2024-04-25
±³À°ÀÏÀÚ : 2024-04-25
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ ¼­¿ï (ÁöÇÏ2Ãþ, ÁöÇÏ1Ãþ, 1Ãþ, 4Ãþ)

±³À°ÁÖÁ¦ : ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (1ÀÏÂ÷)

ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : À̽ÿÂ
¿¬¶ôó : 02-3452-7291  

À̸ÞÀÏ : gbcc@intercom.co.kr

±³À°Á¾·ù : ¿Ü°ú, ¼ºÇü¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ÀÇÇб³À°, ÀÇ·á°æ¿µ

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 30 ½Ã°£ 18ºÐ

¼¼ºÎ¼ö°­·á : 800,000¿ø  

ºñ°í [Á¶±âµî·Ï(2023.11.01-2024.02.01)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 400,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 500,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 150,000[»çÀüµî·Ï(2024.02.02-2024.04.05)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 480,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 600,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 200,000[ÇöÀåµî·Ï(2024.04.25-2024.04.27)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 640,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 800,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 250,000*http://gbcc.kr/Contents.asp?LoadPage=Instruction&Tap=B


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 08:45~09:00 Opening Ceremony ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:00~09:25 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Re-thinking Surgical Management in Ipsilateral Breast Tumor Recurrence Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:25~09:50 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Tailored Axillary Surgery in Axillary Node-Positive Breast Cancer Andrea Barrio(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 09:50~10:15 [Symposium 1: States-of-Art: Personalized Surgery in Breast Cancer] Omission of Breast Surgery in Patients with Exceptional Response to Neoadjuvant Systemic Therapy Tomomi Fujisawa(Gunma Prefectural Cancer Center, Japan)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:00~09:20 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Resistance Mechanism of CDK4/6 Inhibitor: Primary or Acquired Dennis Slamon(Univ. of California, Los Angeles, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:20~09:40 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] What Is the Optimal Treatment Strategy After the First Line CDK4/6 Inhibitor? Yoon-Sim Yap(National Cancer Centre Singapore, Singapore)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 09:40~10:00 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Antibody Drug Conjugate for HR+HER2- MBC In Hae Park(Korea Univ. Guro Hospital, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Room 2 (Grand 1)) 10:00~10:15 [Panel Discussion 1:Optimizing Treatment Sequence After CDK4/6 Inhibitors] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:00~09:25 [Symposium 2: Artificial Intelligence: Past, Present and Future] Practical Considerations and the Implementation of AI Tools for Breast Cancer Risk Prediction Thijs Kooi(Lunit Inc., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:25~09:50 [Symposium 2: Artificial Intelligence: Past, Present and Future] Artificial Intelligence in Real-World Experiences: Perspectives of Radiologists Won Hwa Kim(Kyungpook National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 09:50~10:15 [Symposium 2: Artificial Intelligence: Past, Present and Future] Artificial Intelligence in Breast Pathology: Current Landscape and Future Prospects Miseon Lee(The Catholic Univ. of Korea, Seoul St. Mary)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:00~09:25 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Patients Selection of Robotic and Endoscopic NSM for Beginners Sae Byul Lee(Univ. of Ulsan College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:25~09:50 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Ongoing Studies of Robotic or Endoscopic NSM Chi Wei Mok(Changi General Hospital, Singhealth Duke-NUS Breast Centre, Singapore)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 09:50~10:15 [IERBS 2024 1: Current Status and Issues for Robotic and Endoscopic NSM] Current Application of Robotic and Endoscopic NSM for High Risk of Breast Cancer Patients Deborah Farr(UT Southwestern Harold C. Simmons Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:00~09:20 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Epidemiology and Characteristics of Young Patients with Breast Cancer in Asian Countries Ching-Hung Lin(National Taiwan Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:20~09:40 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Surgical Management of Breast Cancer in Young Asian Patients and Perspectives in Clinical Research Jai Min Ryu(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 09:40~10:00 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Medical Management of Breast Cancer in Young Asian Patients and Perspectives in Clinical Research Chi-Cheng Huang(Taipei Veterans General Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:00~10:15 [GBCC-TBCS Joint Session: Asian Premenopausal Women with Breast Cancer] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:00~09:08 [Oral Presentation 1] EFFECT OF BRCA 1/2 MUTATION ON THE LONG-TERM ONCOLOGIC OUTCOME OF BREAST CANCER PATIENTS WHO UNDERWENT BREAST-CONSERVING SURGERY (KOREA-BSG 06) Chihwan Cha(Hanyang Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:08~09:16 [Oral Presentation 1] THE PERFORMANCE OF MOBILE UNITS VERSUS HOSPITAL UNITS IN NATIONAL BREAST CANCER SCREENING PROGRAM IN TAIWAN, 2010-2020 Pham Thao Vy Vu(Taipei Medical University, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:16~09:24 [Oral Presentation 1] LOW DOSE BREAST CT USING DEEP LEARNING-BASED TECHNIQUE FOR NOISE REDUCTION Myoung Kyoung Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:24~09:32 [Oral Presentation 1] BREAST CANCER RISK GENES ANALYSIS WITH WHOLE GENOME SEQUENCING WITH BRCA 1/2 MUTATION-NEGATIVE BREAST CANCER IN SAMSUNG MEDICAL CENTER Youngji Kwak(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:32~09:40 [Oral Presentation 1] PREOPERATIVE IMPACTING FACTORS ON TUMOR GROWTH DURING THE WAIT TIME FOR BREAST CANCER SURGERY Ikbeom Shin(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:40~09:48 [Oral Presentation 1] A COHORT ON HEALTH-RELATED QUALITY OF LIFE AND PSYCHOLOGICAL HEALTH OF LONG-TERM BREAST CANCER SURVIVORS IN KOREA Thi Xuan Mai Tran(Hanyang University College of Medicine, Vietnam)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:48~09:56 [Oral Presentation 1] A RANDOMIZED CONTROLLED TRIAL INVESTIGATING CLINICAL EFFICACY OF MHEALTH APPS IN BREAST CANCER SURVIVORS Young-Jin Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 09:56~10:04 [Oral Presentation 1] ESTABLISHING AND ADVANCED PRACTICE NURSE (APN)-LED BREAST CANCER SURVIVORSHIP CLINIC AT THE NATIONAL UNIVERSITY CANCER INSTITUTE (NCIS): A YEAR Litang Chen(National University Cancer Institute, Singapore, Singapore)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:04~10:12 [Oral Presentation 1] SUMMARIZING PATIENT MEDICAL RECORDS FOR ACCURATE PHYSICIAN COMMUNICATION: A COMPARISON OF HUMAN VS. AI-BASED APPROACHES Jijung Jung(Seoul National Univ., Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 10:15~10:30 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 10:30~10:55 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] Oral SERDs and Novel Endocrine Therapy Agents Gun Min Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 10:55~11:20 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] Targeting PI3K-AKT-mTOR Pathway in HR+ Breast Cancer Yen-Shen Lu(National Taiwan Univ. Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 11:20~11:45 [Symposium 3: The New Frontier of Endocrine Treatment for Breast Cancer] New Targets in Hormone Receptor Positive Breast Cancer Yeon Hee Park(Samsung Medical Center, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 10:30~10:50 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Need to Complete Removal of Residual Microcalcifications? - In Case Highly Suggestive of Clinical pCR in MRI and with Residual Diffuse Microcalcification in Mammogram Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 10:50~11:10 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Inflammatory Breast Cancer Following Good Response to Neoadjuvant Therapy: No Longer an Absolute Contraindication for Breast Conservation or Skin-Sparing Mastectomy? - Does Initial Extent or Severity Matter? Stephanie M. Wong(Jewish General Hospital Segal Cancer Centre, Canada)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 11:10~11:30 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Young Age Breast Cancer with cT1-3Nx, Low Grade, ER+ Tumor - Upfront Surgery or Neoadjuvant Chemotherapy? Hideko Yamauchi(Univ. of Hawai)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 11:30~11:45 [Panel Discussion 2:Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 10:30~10:55 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Synergy from Surgical Viewpoint: A Holistic Imaging Interpretation with Intraoperative Experience Joon Jeong(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 10:55~11:20 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Synergy from Oncological Viewpoint: Exploring Current Trends and Principles of Chemotherapy Jae-Joon Kim(Pusan National Univ. Yangsan Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 11:20~11:45 [Education Session 1: What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC] Contemporary Imaging Insights and Interpretation Considerations for Patients Undergoing Neoadjuvant Systemic Therapy Kazunori Kubota(Dokkyo Medical Univ. Saitama Medical Center, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 10:30~10:55 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Implication of Dry and Cadaveric Skill Labs for Robotic and Endoscopic NSM Jeffrey Johnson(Mayo Clinic, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 10:55~11:20 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Robotic and Endoscopic NSM in Large & Ptotic Patients Wen-Ling Kuo(Chang Gung Memorial Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 11:20~11:45 [IERBS 2024 2: Initiation and Troubleshooting of Robotic and Endoscopic NSM] Managing Postop-Complications of Robotic and Endoscopic NSM Compared to Open NSM Eisuke Fukuma(Kameda Medical Center, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:30~10:55 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] Asia in Breast Study Group (BIG) David Cameron(The Univ.of Edinburgh, United Kingdom)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 10:55~11:20 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] Collaboration Experience with BIG Sung-Bae Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 11:20~11:45 [Special Session: GBCC-BIG25: Exploring the Significance of BIG in Asia and Opportunities for Collaboration] BIG Patient Partnership Initiative: Developing Clinical Trials through Patient Partnership Carmela Caballero(Breast International Group, Belgium)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:30~10:38 [Oral Presentation 2] EVALUATION OF COMPLIANCE TO ADJUVANT ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR+) EARLY BREAST CANCER IN YOUNG WOMEN (Y-EBC) FROM A TERTIARY CARE CANCER CENTER IN INDIA Jyoti Bajpai(Tata Memorial Center, India)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:38~10:46 [Oral Presentation 2] THE IMPACT OF ADDING GONADOTROPHIN-RELEASING HORMONE AGONIST TO ADJUVANT ENDOCRINE THERAPY IN PREMENOPAUSAL WITH SMALL NODE NEGATIVE HORMONE-POSITIVE BREAST CANCER ON SURVIVAL AND DISEASE RECURRENCE Sarah Alsafi(Al Adan Hospital, Ministry of Health, Kuwait, Kuwait)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:46~10:54 [Oral Presentation 2] COMPARATIVE ONCOLOGICAL OUTCOMES OF PREMENOPAUSAL WOMEN WITH OVARIAN FUNCTION SUPPRESSION AND POSTMENOPAUSAL WOMEN IN ER+/HER2- BREAST CANCER Jijung Jung(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 10:54~11:02 [Oral Presentation 2] A PHASE III TRIAL COMPARING T-DM1 WITH HPD IN OLDER PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER Akihiko Shimomura(National Center for Global Health and Medicine, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:02~11:10 [Oral Presentation 2] DYNAMIC IMPACT OF CLINICOPATHOLOGICAL FEATURES AND TREATMENTS ON SURVIVAL IN PATIENTS WITH SURGICAL BREAST CANCER: A RETROSPECTIVE POPULATION-BASED COHORT STUDY Maoshan Chen(Suining Central Hospital, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:10~11:18 [Oral Presentation 2] NO SURVIVAL DIFFERENCE BETWEEN INITIAL INFILTRATING BREAST CANCERS EITHER DEVELOPING METACHRONOUS CONTRALATERAL BREAST CANCER OR NOT Byeongkwan Park(The Catholic Univ. of Korea, St. Vincent)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:18~11:26 [Oral Presentation 2] SOCIODEMOGRAPHIC, CLINICAL, AND BIOMARKER PREDICTORS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER: A CLASSIFICATION AND REGRESSION TREE (CART) ANALYSIS Juan Adrian Wiranata(Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:26~11:34 [Oral Presentation 2] PROGNOSTIC ANALYSIS ACCORDING TO ADJUVANT CHEMOTHERAPY AND ANTI-HER2 THERAPY FOLLOWING SURGERY IN T1A/B HER2-POSITIVE BREAST CANCER Woochan Park(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 11:34~11:42 [Oral Presentation 2] CLINICAL OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EARLY METAPLASTIC BREAST CANCER Dakyung Seo(Univ. of Ulsan College of Medicine, Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 11:45~12:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 12:00~12:45 [Plenary Lecture 1] Inhibition of the CDK4/6/Rb/Cyclind Pathway in ER+/HER2- Breast Cancer Dennis Slamon(Univ. of California, Los Angeles, U.S.A.)

ÈÞ½Ä 04¿ù 25ÀÏ 12:45~13:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 13:00~13:45 [Satellite Symposium 1: Daiichi-Sankyo & AstraZeneca] ENHERTU, Unlocking New Frontiers in mBC Treatment: From HER2-Positive to HER2-Low Jieun Lee(The Catholic Univ. of Korea, Seoul St. Mary)

ÈÞ½Ä 04¿ù 25ÀÏ 13:45~14:00 Break ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 1 (Vista 1+2) 14:00~14:45 [Plenary Lecture 2] Evidence-Based Breast Radiotherapy: Canadian Experiences Timothy Whelan(McMaster Univ., Canada)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:00~14:15 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Pros Antonio Toesca(Candiolo Cancer Institute, Italy)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:15~14:30 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Cons Andrea Barrio(Memorial Sloan Kettering Cancer Center, U.S.A.)

Åä·Ð 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 14:30~14:45 [IERBS 2024 3: Debate: Does Robot-Assisted NSM Have a Role Ou] Q&A ()

ÈÞ½Ä 04¿ù 25ÀÏ 14:45~15:00 Break ()

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:00~15:20 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Tumor Agnostic Trials Across Subtypes in Metastatic Breast Cancer Giuseppe Curigliano(European Institute of Oncology and Univ. of Milano, Italy)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:20~15:40 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer Janice Tsang(The Univ. of Hong Kong, Hong Kong )

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 15:40~16:00 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Identifying Biological Entity That Is Sensitive to Immune Checkpoint Inhibitors Hee Kyung Ahn(Gachon Univ. Gil Medical Center, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:00~16:15 [Panel Discussion 3: Beyond Borders: Breaking Barriers of Subtypes] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:00~15:25 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Liquid Biopsies Guided Treatment in ER+HER2- Breast Cancer Jisun Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:25~15:50 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Multigene Assays Based Decision for Extended Endocrine Therapy Masakazu Toi(Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 15:50~16:15 [Education Session 2: Biomarkers Guided Treatment in ER+HER2- Breast Cancer] Biomarkers for Neoadjuvant Endocrine Therapy Hyun Jo Youn(Jeonbuk National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:00~15:25 [IERBS 2024 4: PS Session] Robot-Assisted Breast Reconstruction Benjamin Sarfati(Institut Gustave Roussy, France)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:25~15:50 [IERBS 2024 4: PS Session] Robot-Assisted Breast Reconstruction Dong-Won Lee(Yonsei Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 15:50~16:15 [IERBS 2024 4: PS Session] Autologous Breast Reconstruction - Japanese Trend and Our Strategy Hiroki Mori(Tokyo Medical and Dental Univ., Japan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:00~15:25 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy in Upfront Surgery Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:25~15:50 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Jeong Eon Lee(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 15:50~16:15 [GBCC-SSO Joint Session: Where We Are and Where We Go] Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence Ko Un Clara Park(Dana-Farber Brigham Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:00~15:08 [Oral Presentation 3] INTRAOPERATIVE SUPINE MRI FOR BREAST CONSERVING THERAPY: FINAL RESULTS OF AMIGO (ADVANCED MULTI-MODALITY IMAGE GUIDED OPERATING SUITE) PHASE II CLINICAL TRIAL Leah Kim(Yale University School of Medicine, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:08~15:16 [Oral Presentation 3] THE OPTIMAL TIMING OF BREAST CANCER SURGERY AFTER COVID-19 INFECTION: AN OBSERVATIONAL STUDY Zhao Bi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:16~15:24 [Oral Presentation 3] A COMPARATIVE STUDY OF LOCAL RECURRENCE AND PROGNOSIS OF MULTIPLE BREAST CONSERVING SURGERY VERSUS MASTECTOMY IN PATIENTS WITH MULTIPLE IPSILATERAL BREAST CANCER Asuka Kawabata(St. Luke)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:24~15:32 [Oral Presentation 3] MINIMALLY INVASIVE BIOPSY TECHNIQUE PREDICTING BREAST PATHOLOGICAL COMPLETE RESPONS AFTER NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER Zhiqiang Shi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:32~15:40 [Oral Presentation 3] IMPACT OF UNILATERAL MASTECTOMY WITH OR WITHOUT IMMEDIATE BREAST RECONSTRUCTION ON VERTEBRAL ALIGNMENT Jong-Ho Cheun(Seoul National Univ., Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:40~15:48 [Oral Presentation 3] TO DISSECT OR NOT TO DISSECT? PREDICTING ¡Ã 4 AXILLARY LYMPH NODE METASTASES IN EARLY-STAGE BREAST CANCER FROM A SURGEON Damiano Gentile(IRCCS Humanitas Research Hospital, Italy)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:48~15:56 [Oral Presentation 3] ANALYSIS THE NUMBER OF ADDITIONAL NON-SENTINEL LYMPH NODE METASTASIS WHEN ONLY MICROMETASTASIS WAS DETECTED IN THE SENTINEL LYMPH NODE BIOPSY IN FROZEN SECTION AFTER NEOADJUVANT CHEMOTHERAPY FOLLOWED Dong Seung Shin(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 15:56~16:04 [Oral Presentation 3] EVALUATING THE SURVIVAL OUTCOMES IN CN2-3 BREAST CANCER PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY: SENTINEL LYMPH NODE BIOPSY ALONE VS. AXILLARY LYMPH NODE DISSECTION Eunju Shin(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:04~16:12 [Oral Presentation 3] THE EFFECT OF AXILLARY SURGERY ON THE PROGNOSIS OF IBTR AFTER BCS Jongyeon Yoon(ASAN Medical Center, Korea)

ÈÞ½Ä 04¿ù 25ÀÏ 16:15~16:30 Break ()

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:30~16:50 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Treatment Approach in Small HER2+ or TNBC: Upfront Surgery vs Neoadjuvant Chemotherapy? Marios Tasoulis(The Royal Marsden NHS Foundation Trust, United Kingdom)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 16:50~17:10 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Small Luminal a Breast Cancer in Postmenopausal Women: SLNB Omission vs RT Omission? Tadahiko Shien(Okayama Univ. Hospital, Japan)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 17:10~17:30 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Small Luminal a Breast Cancer in Postmenopausal Women: Tailored Approach of Radiotherapy Bum-Sup Jang(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 25ÀÏ Room 2 (Grand 1) 17:30~17:45 [Panel Discussion 4: Subtype-Based Optimization of Locoregional Treatments for Small Tumors] Discussion ()

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 16:30~16:55 [Education Session 3: The Power of Genomics for Breast Cancer] Technology of Genomic Profiling in Breast Cancer: How to Interpret Genomic Testing In Hye Song(ASAN Medical Cente, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 16:55~17:20 [Education Session 3: The Power of Genomics for Breast Cancer] Tumor vs cfDNA Analysis in Breast Cancer Pedram Razavi(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 17:20~17:45 [Education Session 3: The Power of Genomics for Breast Cancer] Actionable Mutations in Breast Cancer: Molecular Insights and Therapeutic Approaches Min Hwan Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 4 (Walker Hall 2) 16:30~17:45 [IERBS 2024 5: Consensus Meeting: Voting Session] Introduction Consensus Meeting of IERBS & Summary of Previous Consensus Meeting of IERBS Hung-Wen Lai(Changhua Christian Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 16:30~16:55 [ABCN Business Meeting] Sharing Wisdom, Sharing Strength: My Personal Leadership Academy Experience Giuseppe Curigliano(European Institute of Oncology and Univ. of Milano, Italy)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 16:55~17:20 [ABCN Business Meeting] Sharing Wisdom, Sharing Strength: My Personal Leadership Experience for Translational Research Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 5 (Art Hall) 17:20~17:45 [ABCN Business Meeting] HR+HER2- Clinically Node-Positive Breast Cancer: What To Do First? Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:30~16:38 [Oral Presentation 4] CLINICAL AND BIOLOGICAL SIGNIFICANCE OF T-CELL RECEPTOR REPERTOIRE IN PATIENTS WITH BREAST CANCER Chun-Yu Liu(National Yang Ming Chiao Tung University, Taiwan)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:38~16:46 [Oral Presentation 4] IMMUNE MARKER EXPRESSION AND PROGNOSIS OF EARLY BREAST CANCER EXPRESSING HER3 Dae-Won Lee(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:46~16:54 [Oral Presentation 4] INTEGRATING CTDNA TO PREDICT RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNE THERAPY IN HER2-LOW TRIPLE-NEGATIVE BREAST CANCERS Zhao Bi(Shandong Cancer Hospital & Institute, China)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 16:54~17:02 [Oral Presentation 4] THE IMPACT OF TREATMENT DELAY ON SURVIVAL OF BREAST CANCER PATIENTS: A NATIONWIDE DATA OF SOUTH KOREAN Young-Jin Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:02~17:10 [Oral Presentation 4] ANALYZING THE RELATIONSHIP BETWEEN MICROBIOME COMPOSITIONS AND TRIPLE-NEGATIVE BREAST CANCER PROGRESSION: MACHINE LEARNING IDENTIFICATION OF MICROBIAL BIOMARKERS AND THERAPEUTIC TARGETS Prihantini Prihantini(Bandung Institute of Technology, Indonesia)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:10~17:18 [Oral Presentation 4] CLINICAL-PATHOLOGICAL CHARACTERISTICS ASSOCIATED WITH MULTIGENE ASSAY RISK SCORES, AND PROGNOSTIC IMPACT OF MULTIGENE RISK SCORES IN PATIENTS WITH INVASIVE LOBULAR CARCINOMA Young-Won Lee(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:18~17:26 [Oral Presentation 4] PREDICTION OF PATHOLOGICAL COMPLETE RESPONSE IN ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER FOLLOWING NEOADJUVANT CHEMOTHERAPY USING THE IHC4 EQUATION Eunhye Kang(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:26~17:34 [Oral Presentation 4] PROTEOMIC ANALYSIS IDENTIFIES ASSOCIATION OF PERIOSTIN, A MATRICELLULAR PROTEIN, WITH HIGH TUMOR STROMA AND IMMUNE EXCLUSION IN TRIPLE NEGATIVE BREAST CANCER Yeonjin Jeon(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 25ÀÏ Room 6 (Grand 4) 17:34~17:42 [Oral Presentation 4] BREAST CANCER CHARACTERISTICS AND MANAGEMENT IN ELDERLY BRCA MUTATION CARRIERS IN HONG KONG Yuk-Kwan Chang(Queen Mary Hospital, Hong Kong)

±âŸ 04¿ù 25ÀÏ Room 3 (Walker Hall 1) 17:45~18:00 KBCS General Assembly ()

½Ä»ç 04¿ù 25ÀÏ Room 1 (Vista 1+2) 18:00~20:00 Welcome Dinner ()

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ : 2018-11-04

±³À°ÀÏÀÚ : 2018-11-04 ±³À°Àå¼Ò : ±×·£µåÈúÆ°È£ÅÚ(È«Àºµ¿) ÄÁº¥¼Ç¼¾ÅÍ ¿Ü ±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 11,028 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,817 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,895 , ´ñ±Û¼ö : 0

[´ë±¸] 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-04-20

±³À°ÀÏÀÚ : 2023-04-20 ±³À°Àå¼Ò : È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸ ÄÁº¥¼ÇȦAB ¿Ü ±³À°ÁÖÁ¦ : 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,976 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,520 , ´ñ±Û¼ö : 0